Medicaid, Drug Pricing at Stake in Midterms — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Health industry leaders are still adapting to President Trump's Washington rules while preparing for potential midterm-driven policy shifts
- November's midterm elections are expected to reshape debates on Medicaid funding and medication pricing, especially if Democrats win control of a chamber of Congress
- Any major health policymaking after the midterms would still require President Trump's signature, limiting what Congress can unilaterally change
- STAT+ based its analysis on interviews with nearly a dozen leaders and lobbyists representing the health industry
- The outcomes will have wide-ranging impacts for America's health system, scientific research, and patients, per STAT+
Why it matters: Health industry stakeholders face a pivotal election that could redraw Medicaid and drug-pricing rules if Democrats take a chamber, yet any legislation still needs Trump's signature — meaning the election outcome alone determines the menu of policy fights, not whether they become law.
Ask SkimNews
